Open AccessAntibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori ‐positive API2– MALT1 ‐negative gastric MALT lymphoma
Author(s) -
Sumida Tomonori,
Kitadai Yasuhiko,
Hiyama Toru,
Shinagawa Kei,
Tanaka Miwako,
Kodama Michiyo,
Masuda Hiroshi,
Ito Masanori,
Tanaka Shinji,
Yoshihara Masaharu,
Chayama Kazuaki
Publication year - 2009
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2009.01139.x
Subject(s) - helicobacter pylori , caga , medicine , gastroenterology , antibody , malt lymphoma , titer , cancer , gastritis , stomach , immunology , biology , biochemistry , virulence , gene
The aim of this study was to clarify predictive factors for response to eradication therapy in cases of Helicobacter pylori ( H. pylori )‐positive API2– MALT1 ‐negative gastric mucosa‐associated lymphoid tissue (MALT) lymphoma. Sixty‐six patients who were examined for H. pylori infection and the presence of the API2–MALT1 chimeric transcript and who underwent H. pylori eradication therapy as first‐line therapy, were enrolled in this study. Immunohistochemical markers (p53, Ki‐67, and BCL10), microsatellite instability, loss of heterozygosity, serum levels of antibodies (anti‐ H. pylori and anti‐CagA), and markers for gastritis (gastrin and pepsinogens) were examined, and the results were compared between patients whose tumors regressed completely after eradication therapy (responders) and patients whose tumors did not regress (non‐responders). Of the 66 patients with localized gastric MALT lymphoma, 47 (71.2%) showed complete remission after eradication therapy. None of the H. pylori ‐negative ( n = 9) and/or API2–MALT1 ‐positive ( n = 7) patients responded to antibacterial treatment. Of 44 patients with H. pylori ‐positive API2–MALT1 ‐negative gastric MALT lymphoma, 38 (86.4%) showed complete remission after eradication therapy. Titers of antibodies against H. pylori and CagA protein were significantly higher in the responders than in the non‐responders ( P = 0.0235 and 0.0089, respectively). No significant difference between the groups was observed for the other factors. In conclusion, measurement of titers of serum antibodies to H. pylori and CagA protein may be useful for predicting the response to eradication therapy in patients with H. pylori ‐positive API2–MALT1 ‐negative gastric MALT lymphoma. ( Cancer Sci 2009; 100: 1075–1081)